220 related articles for article (PubMed ID: 22948695)
1. Clinical trial data as a public good.
Rodwin MA; Abramson JD
JAMA; 2012 Sep; 308(9):871-2. PubMed ID: 22948695
[No Abstract] [Full Text] [Related]
2. Unlocking Health Canada's cache of trade secrets: mandatory disclosure of clinical trial results.
Herder M
CMAJ; 2012 Feb; 184(2):194-9. PubMed ID: 21876028
[No Abstract] [Full Text] [Related]
3. Manufacturers' promotion of off-label drug use: implications for drug safety.
Zieve A; Carome MA
Expert Opin Drug Saf; 2016 Sep; 15(9):1149-51. PubMed ID: 27145440
[No Abstract] [Full Text] [Related]
4. Researchers left to guess at outcomes of most cancer clinical trials.
Twombly R
J Natl Cancer Inst; 2009 Jan; 101(2):72-4. PubMed ID: 19141774
[No Abstract] [Full Text] [Related]
5. Public registration of clinical trials.
Steinbrook R
N Engl J Med; 2004 Jul; 351(4):315-7. PubMed ID: 15269307
[No Abstract] [Full Text] [Related]
6. Clinical trial transparency--antidote to weaker off-label-promotion rules?
Outterson K
N Engl J Med; 2014 Jul; 371(1):1-3. PubMed ID: 24988551
[No Abstract] [Full Text] [Related]
7. Few studies reporting results at US government clinical trials site.
Kuehn BM
JAMA; 2012 Feb; 307(7):651-3. PubMed ID: 22337663
[No Abstract] [Full Text] [Related]
8. A taxpayer-funded clinical trials registry and results database.
Turner EH
PLoS Med; 2004 Dec; 1(3):e60. PubMed ID: 15562322
[TBL] [Abstract][Full Text] [Related]
9. Predictable materiality: a need for common criteria governing the disclosure of clinical trial results by publicly-traded pharmaceutical companies.
Cohen K; Cormier JW; Davar MV
J Contemp Health Law Policy; 2013; 29(2):201-32. PubMed ID: 23837261
[No Abstract] [Full Text] [Related]
10. Court rules that FDA cannot restrict off-label marketing.
Roehr B
BMJ; 2015 Aug; 351():h4367. PubMed ID: 26265632
[No Abstract] [Full Text] [Related]
11. Clinical trials registries: towards improved access to therapeutic data.
Prescrire Int; 2008 Dec; 17(98):256-9. PubMed ID: 19425275
[TBL] [Abstract][Full Text] [Related]
12. Despite vow, drug makers still withhold data.
Berenson A
N Y Times Web; 2005 May; ():A1, C3. PubMed ID: 15952254
[No Abstract] [Full Text] [Related]
13. The need for improved access to FDA reviews.
O'Connor AB
JAMA; 2009 Jul; 302(2):191-3. PubMed ID: 19584349
[No Abstract] [Full Text] [Related]
14. Free speech rights outweigh restrictions on promoting drugs off label, court rules.
Roehr B
BMJ; 2012 Dec; 345():e8324. PubMed ID: 23220261
[No Abstract] [Full Text] [Related]
15. Avoiding legal and ethical pitfalls of industry-sponsored research: the co-existence of research, scholarship, and marketing in the pharmaceutical industry.
Dorfman HL; Reig LP
Food Drug Law J; 2004; 59(4):595-615. PubMed ID: 15880876
[No Abstract] [Full Text] [Related]
16. Despite law, fewer than one in eight completed studies of drugs and biologics are reported on time on ClinicalTrials.gov.
Law MR; Kawasumi Y; Morgan SG
Health Aff (Millwood); 2011 Dec; 30(12):2338-45. PubMed ID: 22147862
[TBL] [Abstract][Full Text] [Related]
17. Pharmaceuticals and the health of the public: use, safety, cost, access, ethics, and quality.
Zito JM
Med Care; 2012 Nov; 50(11):907-9. PubMed ID: 23047777
[No Abstract] [Full Text] [Related]
18. Evidence-based promotion.
Mattes JA
Am J Psychiatry; 2004 Oct; 161(10):1928; author reply 1929. PubMed ID: 15466002
[No Abstract] [Full Text] [Related]
19. Clinical trial transparency: a reassessment of industry compliance with clinical trial registration and reporting requirements in the United States.
Lassman SM; Shopshear OM; Jazic I; Ulrich J; Francer J
BMJ Open; 2017 Sep; 7(9):e015110. PubMed ID: 28942418
[TBL] [Abstract][Full Text] [Related]
20. Confidentiality laws and secrecy in medical research: improving public access to data on drug safety.
Kesselheim AS; Mello MM
Health Aff (Millwood); 2007; 26(2):483-91. PubMed ID: 17339677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
